---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-202881"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T09:10:20.426311+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q2 net loss narrows to $20.6M; cash $630.9M; NUV-868 studies enrolling

## Summary
- Net loss of $20.6M ($0.09/share) vs $34.9M ($0.16/share) in Q2 2022.
- Cash, cash equivalents and marketable securities of $630.9M as of June 30, 2023.
- R&D expenses decreased to $18.6M from $28.9M, partly due to NUV-422 program termination.
- Phase 1b combo study of NUV-868 with olaparib/enzalutamide and Phase 1 monotherapy enrolling.
- Expects to submit IND for first DDC candidate by year end 2023; formed Scientific Advisory Board.

## SEC filing metadata
- accession: 0001193125-23-202881
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312523202881/0001193125-23-202881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312523202881/d517241d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-202881
- JSON: https://secwatch.observer/filing/0001193125-23-202881.json
- Plain text: https://secwatch.observer/filing/0001193125-23-202881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.